This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Sumitomo Dainippon Pharma Co., Ltd.

Drug Names(s): BBI-608, napabucasin, BB608

Description: BBI608 is an orally administered, first-in-class, anti-cancer small molecule. BBI608, designed to inhibit cancer stem cell pathways by targeting the STAT3 pathway, simultaneously inhibits multiple keycancer cell stemness pathways. BBI608 targets highly malignant cancer stem cells (CSCs) as well asheterogeneous cancer cells.

CSCs are considered to be fundamentally responsible for malignant growth, metastasis, andrecurrence. These cells are a subpopulation of cancer cells that have self-renewal abilityand can differentiate into the heterogeneous cancer cells that comprise the bulk of thetumor mass. CSCs have been isolated from almost every major type of cancer, and havebeen found to be intrinsically resistant to current cancer therapies.

Deal Structure: Boston Biomedical and Dainippon Sumitomo
In April 2011, Dainippon Sumitomo (DSP) and Boston Biomedical (BBI) announced that they signed a Product Option License Agreement for BBI608 for all oncology indications in Japan and exclusive right of negotiation for BBI608 for the United States and Canada.

Under the terms of the agreement, BBI will receive $15 million of upfront payment and clinical trial support upon signing. Based on the outcome of the ongoing clinical trials, DSP has the option to acquire exclusive rights for the development and commercialization for BBI608 in Japan. In addition, DSP has an exclusive negotiation right for the United States and Canada for a certain time.

During this option agreement period, DSP will pay a maximum of $55 million for part of the development costs of BBI608 and for continuation of the option. Assuming DSP exercise the option for Japan, upon successful clinical development and commercialization of BBI608 in Japan, BBI could...See full deal structure in Biomedtracker

BBI608 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug